Sativex
GW Pharma takes back control of UK Sativex sales from Bayer
March 2, 2020Sales and Marketing Bayer, GW Pharma, Sativex, UK
British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …
NHS to utilise first-ever cannabis-based therapies following NICE recommendation of two GW Pharma drugs
November 11, 2019Sales and Marketing Epidyolex, GW Pharma, NHS, Sativex, pharma
The NHS is authorised to use its first two cannabis-based medicines for routine use after NICE saw fit to recommend …
Otsuka, GW announce Sativex fails in Phase III cancer pain trials
October 28, 2015Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure
Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Charities must be clear about pharma funding
October 1, 2014Medical Communications, Sales and Marketing ABPI, NICE, Sativex, charity, funding, mind, pharma
There is growing need for transparency around patient groups and health charities as they are widely perceived to be independent …
Bayer launches world’s first cannabis-derived prescription drug
June 21, 2010Sales and Marketing Bayer, GW Pharmaceuticals, Sativex
Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK. Sativex treats the spasticity symptoms of multiple …
Cannabis-derived MS drug filed for European approval
May 20, 2009Research and Development, Sales and Marketing GW, Sativex
Sativex, the cannabis-derived product developed by GW Pharmaceuticals, could be finally set for European approval after five years of delay. …
Cannabis-derived MS treatment filed in Europe
September 5, 2006Sales and Marketing GW Pharmaceuticals, Sativex
Sativex, the cannabis-derived product developed by GW Pharmaceuticals could be finally set for approval after a delay of around two …
Patient demand brings Sativex to UK ahead of approval
November 17, 2005Sales and Marketing GW Pharmaceuticals, Sativex
The unlicensed cannabis-based medicine Sativex will be available in the UK to treat neuropathic pain on a named patient basis …
Latest content
FibroFind appoints Lee Borthwick as CEO
